{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:57:30Z","timestamp":1790013450608,"version":"4.0.1"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,3,1]]},"DOI":"10.1001\/jama.2022.1271","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T16:48:00Z","timestamp":1646153280000},"page":"846","source":"Crossref","is-referenced-by-count":90,"title":["Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation"],"prefix":"10.1001","volume":"327","author":[{"given":"Tara","family":"Gomes","sequence":"first","affiliation":[{"name":"Li Ka Shing Knowledge Institute of St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya J.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute of St Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie A.","family":"Kitchen","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Garg","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Collaboration for Outcomes Research and Evaluation, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Bozinoff","sequence":"additional","affiliation":[{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Men","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Munro","sequence":"additional","affiliation":[{"name":"Lived Experience Advisory Group, Ontario Drug Policy Research Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute of St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Family and Community Medicine, St Michael\u2019s Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Werb","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute of St Michael\u2019s Hospital, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wyman","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"joi220012r1","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"joi220012r2","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders.","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"5","key":"joi220012r3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1037\/a0037550","article-title":"A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes.","volume":"22","author":"Proctor","year":"2014","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"joi220012r4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder.","volume":"87","author":"Bell","year":"2020","journal-title":"Biol Psychiatry"},{"key":"joi220012r5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment.","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"joi220012r6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade.","volume":"91","author":"Williams","year":"2018","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"joi220012r7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"1","key":"joi220012r8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u201d: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients\u2019 lives.","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"key":"joi220012r10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies.","volume":"74","author":"Priest","year":"2019","journal-title":"Int J Drug Policy"},{"key":"joi220012r11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108031","article-title":"One year of methadone maintenance treatment in a fentanyl endemic area.","volume":"115","author":"Stone","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"7497","key":"joi220012r15","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","article-title":"Reader\u2019s guide to critical appraisal of cohort studies: 2. assessing potential for confounding.","volume":"330","author":"Mamdani","year":"2005","journal-title":"BMJ"},{"key":"joi220012r16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108196","article-title":"Medication treatment for opioid use disorder in the age of COVID-19.","volume":"122","author":"Nunes","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"joi220012r18","first-page":"1","article-title":"COVID-19-related policy changes for methadone take-home dosing.","author":"Levander","year":"2021","journal-title":"Subst Abus"},{"issue":"6","key":"joi220012r19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era.","volume":"47","author":"Amram","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"joi220012r20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13722-021-00281-3","article-title":"Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19.","volume":"16","author":"Levander","year":"2021","journal-title":"Addict Sci Clin Pract"},{"key":"joi220012r22","doi-asserted-by":"crossref","first-page":"m772","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency.","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"issue":"8","key":"joi220012r23","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/add.v113.8","article-title":"The impact of buprenorphine and methadone on mortality.","volume":"113","author":"Hickman","year":"2018","journal-title":"Addiction"},{"key":"joi220012r14"},{"key":"joi220012r9","unstructured":"Substance Abuse and Mental Health Services Administration. Federal guidelines for opioid treatment programs. Published 2015. Accessed January 11, 2022.? https:\/\/store.samhsa.gov\/sites\/default\/files\/d7\/priv\/pep15-fedguideotp.pdf"},{"key":"joi220012r12","unstructured":"Substance Abuse and Mental Health Services Administration. Opioid treatment program (OTP) guidance. Published 2020. Accessed January 11, 2022.? https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf"},{"key":"joi220012r13","unstructured":"Centre for Addiction and Mental Health. COVID-19 Opioid Agonist Treatment Guidance. Published 2020. Updated August 2021. Accessed October 20, 2021.? https:\/\/www.camh.ca\/\/-\/media\/files\/covid-19-modifications-to-opioid-agonist-treatment-delivery-pdf.pdf?la=en&hash=261C3637119447097629A014996C3C422AD5DB05"},{"key":"joi220012r17","unstructured":"British Columbia Centre on Substance Use. Risk mitigation in the context of dual public health emergencies. Published 2020. Accessed January 11, 2022.? https:\/\/www.bccsu.ca\/wp-content\/uploads\/2020\/05\/Risk-Mitigation-in-the-Context-of-Dual-Public-Health-Emergencies-v1.6.pdf"},{"key":"joi220012r21","unstructured":"SAMHSA extends the methadone take-home flexibility for one year while working toward a permanent solution [press release]. November 18, 2021. Accessed January 11, 2022. https:\/\/www.samhsa.gov\/newsroom\/press-announcements\/202111181000#:~:text=The%20Substance%20Abuse%20and%20Mental,COVID%2D19%20Public%20Health%20Emergency"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2789543\/jama_gomes_2022_oi_220012_1645750110.23902.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T16:48:07Z","timestamp":1646153287000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2789543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.1271","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}